Cargando…

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

Oridonin (Ori) is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens and has anti-inflammatory activity, but the target of Ori remains unknown. NLRP3 is a central component of NLRP3 inflammasome and has been involved in a wide variety of chronic inflammation-dri...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Hongbin, Jiang, Hua, Chen, Yun, Ye, Jin, Wang, Aoli, Wang, Chao, Liu, Qingsong, Liang, Gaolin, Deng, Xianming, Jiang, Wei, Zhou, Rongbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026158/ https://www.ncbi.nlm.nih.gov/pubmed/29959312 http://dx.doi.org/10.1038/s41467-018-04947-6

Ejemplares similares

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
por: Jiang, Hua, et al.
Publicado: (2017)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018)

An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups
por: Lin, Hualong, et al.
Publicado: (2022)

Oridonin supplementation attenuates atherosclerosis via NLRP-3 inflammasome pathway suppression
por: Sultan, Ahmed, et al.
Publicado: (2023)

Oridonin Alleviates LPS-Induced Depression by Inhibiting NLRP3 Inflammasome via Activation of Autophagy
por: Li, Chunyan, et al.
Publicado: (2022)

Oridonin ameliorates carbon tetrachloride‐induced liver fibrosis in mice through inhibition of the NLRP3 inflammasome
por: Liu, Dong, et al.
Publicado: (2020)

Neuroprotective Effect of Oridonin on Traumatic Brain Injury via Inhibiting NLRP3 Inflammasome in Experimental Mice
por: Yan, Chaolong, et al.
Publicado: (2020)

Inhibition of the NLRP3 Inflammasome Activation by Manoalide Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
por: Li, Cong, et al.
Publicado: (2022)

Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage
por: Hou, Yingting, et al.
Publicado: (2023)

Oridonin Attenuates Myocardial Ischemia/Reperfusion Injury via Downregulating Oxidative Stress and NLRP3 Inflammasome Pathway in Mice
por: Lu, Chuanghong, et al.
Publicado: (2020)

Inhibition of the Inflammasome Activity of NLRP3 Attenuates HDM-Induced Allergic Asthma
por: Ma, Ming, et al.
Publicado: (2021)

Covalent targeting as a common mechanism for inhibiting NLRP3 inflammasome assembly
por: Stanton, Caroline, et al.
Publicado: (2023)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
por: Xu, Haowen, et al.
Publicado: (2023)

Oridonin alleviates the inhibitory effect of lipopolysaccharide on the proliferation and osteogenic potential of periodontal ligament stem cells by inhibiting endoplasmic reticulum stress and NF-κB/NLRP3 inflammasome signaling
por: Jiang, Junhao, et al.
Publicado: (2023)

Investigation of the anti-asthmatic activity of Oridonin on a mouse model of asthma
por: Wang, Jing, et al.
Publicado: (2016)

CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation
por: Tang, Tiantian, et al.
Publicado: (2017)

The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells
por: Vasaturo, Michele, et al.
Publicado: (2018)

Boron-Based Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2017)

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
por: Mezzaroma, Eleonora, et al.
Publicado: (2021)

Perfluorodecanoic acid stimulates NLRP3 inflammasome assembly in gastric cells
por: Zhou, Xiangyu, et al.
Publicado: (2017)

NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors
por: Xu, Yi, et al.
Publicado: (2023)

NLRP3 inflammasome and its inhibitors: a review
por: Shao, Bo-Zong, et al.
Publicado: (2015)

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020)

Anti-NLRP3 Inflammasome Natural Compounds: An Update
por: Liu, Baolong, et al.
Publicado: (2021)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)
por: Zhang, Xiaolu, et al.
Publicado: (2023)

NLRP3 inflammasome in endothelial dysfunction
por: Bai, Baochen, et al.
Publicado: (2020)

Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice
por: Wang, Lei, et al.
Publicado: (2023)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

The role of NLRP3 inflammasome in digestive system malignancy
por: Sun, Cen-Cen, et al.
Publicado: (2022)

Oridonin Prolongs the Survival of Mouse Cardiac Allografts by Attenuating the NF-κB/NLRP3 Pathway
por: Du, Xiaoxiao, et al.
Publicado: (2021)

Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
por: Yang, Yang, et al.
Publicado: (2019)

Role of NLRP3 inflammasome in systemic sclerosis
por: Lin, Cong, et al.
Publicado: (2022)

ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation
por: Li, Shuhang, et al.
Publicado: (2021)

Homotypic CARD-CARD interaction is critical for the activation of NLRP1 inflammasome
por: Xu, Zhihao, et al.
Publicado: (2021)

Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome
por: Zhang, Tan, et al.
Publicado: (2021)

Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis
por: Jiang, Chunteng, et al.
Publicado: (2021)

Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2018)

Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models
por: Das, Biswadeep, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sec6n04igd7kkgpv9so6j365he